Products with Anti-estrogenic effect bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2738 | Tracheloside |
| Tracheloside significantly decreases the activity of alkaline phosphatase (AP), an estrogen-inducible marker enzyme, with an IC(50) value of 0.31 microg/ml, a level of inhibition comparable to that of tamoxifen (IC(50) = 0.43 microg/ml). | |
| BCN2964 | Cyclopamine |
| Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay, it can increase levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cyclopamine as a novel, potent inhibitor of human breast cancer proliferation and estrogen responsiveness that could potentially be developed into a promising therapeutic agent for the treatment of breast cancer. Cyclopamine also can suppress the growth of leukemia and lymphoma cells. | |
| BCN3949 | Coumestrol |
| 1. Coumestrol suppresses the accumulation of HIF-1α via suppression of SPHK1 pathway in hypoxic PC-3 cells. 2. Coumestrol is a novel inducer of mitochondrial biogenesis through the activation of Sirt1. 3. Coumestrol can function by inhibiting oncogenic disease, at least in part, through CKII inhibition-mediated cellular senescence. 4. Coumestrol treatment is effective in preventing neuronal loss in all times of administration as well as able to rescue the Na+, K+ -ATPase activity, suggesting its potential benefits for either prevention or therapeutics use against cerebral ischemia in males. | |
| BCN3978 | Isoerysenegalensein E |
| 1. Isoerysenegalensein E shows significant cytotoxicity against HL-60 cells, it induces apoptosis in HL-60 cells through activation of the caspase-9/caspase-3 pathway, which is triggered by mitochondrial dysfunction. 2. Isoerysenegalensein E shows anti-estrogenic activity comparable to that of 4-hydroxytamoxifen, a typical estrogen receptor antagonist. | |
| BCN4602 | 6,8-Diprenylorobol |
| 1. 6,8-Diprenylorobol possesses weaker anti-H. pylori activity, it may be a useful chemopreventive agent for peptic ulcer or gastric cancer in H. pylori-infected individuals. 2. 6,8-Diprenylorobol shows anti-estrogenic activity comparable to that of 4-hydroxytamoxifen, a typical estrogen receptor (ER) antagonist. 3. 6,8-Diprenylorobol shows promising cytotoxic effects toward HL-60 cells (IC50 4.3 ± 0.7 to 18.0 ± 1.7 uM). 4. 6,8-Diprenylorobol has antioxidant activity, it can reduce A2E photooxidation in a dose dependent manner. 5. 6,8-Diprenylorobol is evaluated against the AIDS-related opportunistic fungal pathogens, Candida albicans and Cryptococcus neoformans. 6. 6,8-Diprenylorobol can protect against 6-OHDA-induced neurotoxicity by enhancing the ubiquitin/proteasome-dependent degradation of α-synuclein and synphilin-1, suggesting that it may be a possible candidate for the treatment of neurodegenerative diseases. | |
